Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: dichlorphenamide
Trade Name:
Date Designated: 09/02/2010
Orphan Designation: Treatment of primary periodic paralyses
Orphan Designation Status: Designated/Approved
Xeris Pharmaceuticals, Inc.
180 N La Salle Street, Suite 1600
Chicago, Illinois 60601
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: dichlorphenamide
Trade Name:
Marketing Approval Date: 08/07/2015
Approved Labeled Indication: Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants
Exclusivity End Date: 08/07/2022 
Exclusivity Protected Indication* :  Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-